The annual meeting of the American Association for Cancer Research (AACR) will be held on April 5-10, 2024, local time in San Diego, USA. As one of the world's most influential academic events in the field of oncology, the AACR Annual Meeting focuses on all aspects of oncology research and innovation, and releases cutting-edge research results in the field of global oncology. Recently, AACR officially released the information of selected studies, and five studies of two innovative drugs, namely, Anrotinib (small molecule multi-targeted receptor tyrosine kinase inhibitor) and TQB2916 (CD40 agonist) from Chiatai Tianqing Pharmaceutical Group, have been selected.

Clinical Studies

ALTER-G-001 A Multicohort, Multicenter, Phase II Study - Cohort C Results Update: Anlotinib in Combination with Chemotherapy for First-Line Treatment of Digestive Tract Tumors with Unresectable Liver Metastases
CT213/13 - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Correspondence should be addressed to ZHANG Jun, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
First author: Junwei Wu, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Efficacy of second-line treatment after treatment with first-line immunocombination chemotherapy in patients with extensive small-cell lung cancer.
5098/20 - Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy
Correspondence should be addressed to WANG Jie, Cancer Hospital, Chinese Academy of Medical Sciences, China.
First author: Rui Wan, Cancer Hospital, Chinese Academy of Medical Sciences, China

Phase I clinical study of TQB2916, a novel CD40 agonist, in subjects with advanced malignancies
CT192 / 20 - A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
Principal Investigator: Ba Yi

Basic Research

Ubiquitin-specific protease 18 (USP18) ameliorates amlotinib resistance in medullary thyroid carcinoma by stabilizing Aurora B kinase
4665/18 - USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase
Correspondence should be addressed to ZHENG Qianqian, Cancer Hospital, Tianjin Medical University, China.
First author: Qin Xuan, Cancer Hospital of Tianjin Medical University, China

Amlotinib in combination with PARP inhibitor as a bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer
3997/6 - PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer
Correspondence should be addressed to Gao Qinglei and Fang Yong, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
First author: Huayu Li, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

About Anrotinib
Amrotinib is an oral novel small molecule multi-targeted receptor tyrosine kinase inhibitor (TKI) independently developed by Chiatai Tianqing Pharmaceutical Group, which can effectively inhibit kinases such as VEGFR 1-3, PDGFR α/β, FGFR 1-4, c-Kit, etc., and achieves inhibition of tumor neovascularization, inhibition of tumor growth, and modulation of the immune microenvironment by regulating the reprogramming of the tumor microenvironment. In May 2018, Anrotinib hydrochloride capsule was approved by the State Drug Administration to be listed on the market, which is the first drug approved for third-line treatment of advanced non-small cell lung cancer in China. Anrotinib hydrochloride capsules have been approved for five indications in China: third-line non-small cell lung cancer, third-line small cell lung cancer, soft tissue sarcoma, medullary thyroid carcinoma, and differentiated thyroid cancer.In January 2023, the marketing application for the sixth indication of anrotinib hydrochloride capsules was formally accepted by the CDE for the first-line treatment of bemosubicin (TQB2450, a PD-L1 inhibitor) in combination with bemosubicin (PD-L1 inhibitor) and chemotherapy for Small Cell Lung Cancer. In February 2024, a marketing application was formally accepted by the CDE for the seventh indication of amlotinib hydrochloride capsules for the treatment of recurrent or metastatic endometrial cancer in combination with bemosubaisumab.

About TQB2916 (CD40 agonist)
TQB2916 is an agonistic, fully human IgG2 monoclonal antibody targeting CD40, which acts as a tumor suppressor by promoting immune cell activation through activation of antigen-presenting cells (APCs). TQB2916 is a fully human IgG2 monoclonal antibody that targets CD40 and has been shown to activate B cells and dendritic cells, which in turn activate T cells to secrete IFN-γ. Preclinical in vivo results showed that TQB2916 significantly inhibited the growth of tumors in an animal model. Currently, there is no CD40 agonist approved for marketing in the world, and similar products show potential development prospects in pancreatic cancer, soft tissue sarcoma, melanoma, esophageal cancer and other fields.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650365624&idx=1&sn=20783923216ffee013f9f4ecd18b8491&chksm=885f9b0fbf281219634f435df6e694765a6b7ed8e832226ace1e290aaf79edf4d152e1efd402&mpshare=1&scene=1&srcid=0312D14M6ZwZuiXIyE4Fv8AO&sharer_shareinfo=a740753cdc9b1b7fd56c65c7cdab28d7&sharer_shareinfo_first=a740753cdc9b1b7fd56c65c7cdab28d7&poc_token=HEem72Wjifs3KDKqwtc3oyoXdvawtxwwuuH2J6fq